A research and development (R&D) tax rebate of nearly $5 million from the Australian Government will boost Radiopharm Theranostics’ mission to further develop its suite of diagnostic and therapeutic products aimed at beating the cancer scourge.
The rebate recognises the company’s R&D activity during the 2023 financial year and comes as it prepares to run clinical pancreatic cancer trials…
